Amgen Defies FDA Withdrawal Request for Drug Linked to Liver Failure

Thousand Oaks, Tuesday, 7 April 2026.
Despite eight reported deaths and an FDA withdrawal request, Amgen continues marketing its drug Tavneos, risking significant legal and financial fallout over severe liver failure complications.